Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. reported its third quarter 2026 financial results, emphasizing the first marketing authorizations for its drugs BOT and BAL. The company is advancing its global Phase 3 ROBBIN trial, targeting high-risk Stage II and III microsatellite-stable colon cancer patients. This trial involves the use of botensilimab and balstilimab before surgery.

Market Sentiment Analysis

POSITIVE FACTORS

  • First marketing authorizations for BOT and BAL.
  • Progress in the Phase 3 ROBBIN trial.
  • Focus on high-risk Stage II and III colon cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+203%
120-day peak, hindsight
Typical move
5.5%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
AGEN2034
Phase 2 · Advanced Cancer

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the third quarter ended September 30, 2026, and highlighted progress preparing its global randomized Phase 3 ROBBIN trial of botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, before surgery in patients with high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer. The cli

Frequently Asked Questions

What financial results did Agenus report?

Agenus reported its financial results for the third quarter ended September 30, 2026.

What is the ROBBIN trial about?

The ROBBIN trial studies botensilimab and balstilimab in high-risk colon cancer patients.

What are BOT and BAL?

BOT is an anti-CTLA-4 antibody, and BAL is an anti-PD-1 antibody.

What stage of cancer is the ROBBIN trial targeting?

The trial targets high-risk Stage II and Stage III microsatellite-stable colon cancer.

ShareAdd on Google
Tags: AGEN Agenus BOT BAL Phase 3 ROBBIN immuno-oncology
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
AGEN2034Phase 2
Advanced Cancer →

Catalyst track record

+203%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →